Enlivex enrolls 135 patients in phase 2b knee osteoarthritis trial
Enlivex Ltd. (ENLV) has enrolled 135 patients in its Phase 2b trial for knee osteoarthritis, with topline data expected by mid-2027. The trial evaluates Allocetra's efficacy and safety in 182 patients across the U.S., Denmark, and Poland. The FDA granted RMAT designation to the therapy in July 2026.
How this was made
The 30-second read
Why it matters
The enrollment update provides the first quantitative progress metric for the Phase 2b study, setting the stage for upcoming efficacy readouts.
Market read
The news is a primary disclosure for a micro‑cap biotech, likely to generate short‑term buying interest ahead of data release.
What to watch
The trial still has 47 patients to enroll and six‑month data are months away; current price may already reflect optimism.
Background
Enlivex is developing Allocetra, a Regenerative Medicine Advanced Therapy (RMAT) for knee osteoarthritis, a disease with no disease‑modifying treatments.
Ticker impact
Enlivex reported that 135 of the planned 182 patients have been randomized and received the first injection in its Phase 2b knee osteoarthritis trial.
likely upward pressure as investors price in potential positive Phase 2b results
First‑report of patient randomization in a late‑stage trial for a biotech with no approved therapy in the space; market typically reacts favorably to progress milestones.
Market effects
May boost broader regenerative‑medicine and osteoarthritis‑therapy stocks as the trial advances.
Limited to US biotech investors; no broader regional effect.
Modest, confined to niche biotech and healthcare investors.
Counterpoint
If the trial encounters safety issues or fails to meet endpoints, the early enrollment could be a false positive for the stock.
Key entities
- companyEnlivex Ltd.
Biotech company conducting the Phase 2b trial.
- productAllocetra
Investigational intra‑articular injection for knee osteoarthritis.
